265 related articles for article (PubMed ID: 29292876)
21. Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.
Biggin A; Munns CF
Curr Osteoporos Rep; 2017 Oct; 15(5):412-418. PubMed ID: 28823022
[TBL] [Abstract][Full Text] [Related]
22. Treatment response to long term antiresorptive therapy in osteogenesis imperfecta type VI: does genotype matter?
Celik NB; Gonc N; Ozon A; Alikasifoglu A; Rauch F; Kandemir N
J Pediatr Endocrinol Metab; 2020 Dec; 33(12):1617-1624. PubMed ID: 33031053
[TBL] [Abstract][Full Text] [Related]
23. [Treatment with bisphosphonates improves the quality of life in patients with diagnosis of osteogenesis imperfecta].
Cuevas-Olivo R; Alejo-Fuentes LJ; Alejo-Fuentes LF; Campos-Angulo G
Acta Ortop Mex; 2019; 33(2):63-66. PubMed ID: 31480105
[TBL] [Abstract][Full Text] [Related]
24. Curative Cell and Gene Therapy for Osteogenesis Imperfecta.
Schindeler A; Lee LR; O'Donohue AK; Ginn SL; Munns CF
J Bone Miner Res; 2022 May; 37(5):826-836. PubMed ID: 35306687
[TBL] [Abstract][Full Text] [Related]
25. Functional significance of bone density measurements in children with osteogenesis imperfecta.
Huang RP; Ambrose CG; Sullivan E; Haynes RJ
J Bone Joint Surg Am; 2006 Jun; 88(6):1324-30. PubMed ID: 16757767
[TBL] [Abstract][Full Text] [Related]
26. Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.
Folkestad L
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619932
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonate therapy for osteogenesis imperfecta.
Phillipi CA; Remmington T; Steiner RD
Cochrane Database Syst Rev; 2008 Oct; (4):CD005088. PubMed ID: 18843680
[TBL] [Abstract][Full Text] [Related]
28. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
[TBL] [Abstract][Full Text] [Related]
29. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
30. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
31. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
32. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta.
Rauch F; Lalic L; Roughley P; Glorieux FH
J Bone Miner Res; 2010 Jun; 25(6):1367-74. PubMed ID: 19929435
[TBL] [Abstract][Full Text] [Related]
33. [Bisphosphonates and other new therapeutic agents for the treatmednt of osteogenesis imperfecta].
Yamashita S
Clin Calcium; 2009 Feb; 19(2):253-7. PubMed ID: 19182368
[TBL] [Abstract][Full Text] [Related]
34. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
[TBL] [Abstract][Full Text] [Related]
35. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.
Bishop N; Adami S; Ahmed SF; Antón J; Arundel P; Burren CP; Devogelaer JP; Hangartner T; Hosszú E; Lane JM; Lorenc R; Mäkitie O; Munns CF; Paredes A; Pavlov H; Plotkin H; Raggio CL; Reyes ML; Schoenau E; Semler O; Sillence DO; Steiner RD
Lancet; 2013 Oct; 382(9902):1424-32. PubMed ID: 23927913
[TBL] [Abstract][Full Text] [Related]
36. Mitigating the Denosumab-Induced Rebound Phenomenon with Alternating Short- and Long-Acting Anti-resorptive Therapy in a Young Boy with Severe OI Type VI.
Seale E; Molina MO; Carsen S; Sheffield H; Koujok K; Robinson ME; Feber J; Smit K; Page M; Walker S; Khan N; Konji VN; Rauch F; Ward LM
Calcif Tissue Int; 2023 May; 112(5):613-620. PubMed ID: 36867194
[TBL] [Abstract][Full Text] [Related]
37. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
[TBL] [Abstract][Full Text] [Related]
38. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
39. New trends in the treatment of osteogenesis imperfecta type III - own experience.
Jakubowska-Pietkiewicz E; Chlebna-Sokół D
Ortop Traumatol Rehabil; 2008; 10(6):593-601. PubMed ID: 19153548
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
